The CMN-001-1 study and kidney cancer
The CMN-001-1 study is researching an investigational medicine designed to improve the way your body’s immune system responds to your advanced kidney cancer, or renal cell carcinoma (RCC). The goal is to see how it works in combination with standard RCC cancer care, which all participants will receive.
Joining the CMN-001-1 study
If you have kidney cancer (specifically, renal cell carcinoma) and you have not received any cancer treatment, you may be able to join.
Study participants can expect the following during the study:
Aside from the investigational study therapy, the tests, assessments, and standard kidney cancer therapy you receive in the study are similar to the routine care doctors provide to people with advanced RCC.